Oncotelic Therapeutics (OTLC) Short Interest Ratio & Short Volume → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free OTLC Stock Alerts $0.04 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Oncotelic Therapeutics Short Interest DataCurrent Short Volume1,800 sharesPrevious Short Volume11,400 sharesChange Vs. Previous Month-84.21%Dollar Volume Sold Short$71.91Short Interest Ratio / Days to Cover0.0Last Record DateApril 30, 2024Outstanding Shares398,670,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume58,266 sharesAverage Trading Volume63,606 sharesToday's Volume Vs. Average92% Short Selling Oncotelic Therapeutics ? Sign up to receive the latest short interest report for Oncotelic Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatOTLC Short Interest Over TimeOTLC Days to Cover Over TimeOTLC Percentage of Float Shorted Over Time Ad Crypto 101 MediaA ‘DeFi Summer’ Projected!Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. Oncotelic Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,800 shares $71.91 -84.2%N/A0 $0.04 4/15/202411,400 shares $468.54 +2,750.0%N/A0.1 $0.04 3/31/2024400 shares $14.39 -89.7%N/A0 $0.04 3/15/20243,900 shares $144.69 -75.2%N/A0.1 $0.04 2/29/202415,700 shares $554.21 -90.9%N/A0.1 $0.04 2/15/2024172,400 shares $6,637.40 +34.8%N/A0.9 $0.04 Get the Latest News and Ratings for OTLC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024111,900 shares $4,420.05 +27,875.0%N/A1.2 $0.04 12/31/2023400 shares $15.30 No ChangeN/A0 $0.04 12/15/2023400 shares $15.76 No ChangeN/A0 $0.04 11/30/2023400 shares $16.28 -97.6%N/A0 $0.04 11/15/202316,700 shares $542.75 -58.2%N/A0 $0.03 10/31/202339,900 shares $1,312.71 +66.3%N/A0.1 $0.03 10/15/202324,000 shares $816.00 +1,400.0%N/A0.1 $0.03 9/30/20231,600 shares $49.60 -95.4%N/A0 $0.03 9/15/202334,500 shares $1,086.75 -52.7%N/A0.1 $0.03 8/31/202372,900 shares $1,909.98 +138.2%N/A0.2 $0.03 8/15/202330,600 shares $703.80 -4.7%N/A0.3 $0.02 7/31/202332,100 shares $767.19 -50.3%N/A0.1 $0.02 7/15/202364,600 shares $1,627.92 +12.0%N/A0.1 $0.03 6/30/202357,700 shares $1,442.50 +1,054.0%N/A0 $0.03 6/15/20235,000 shares $150.00 -79.8%N/A0 $0.03 5/31/202324,700 shares $768.17 +6,075.0%N/A0.1 $0.03 5/15/2023400 shares $14.76 -55.6%N/A0 $0.04 4/30/2023900 shares $37.80 +125.0%N/A0 $0.04 4/15/2023400 shares $20.40 -99.1%N/A0 $0.05 3/31/202342,900 shares $2,037.75 +164.8%N/A0.3 $0.05 3/15/202316,200 shares $920.16 No ChangeN/A0.1 $0.06 2/28/202316,200 shares $891.00 -57.7%N/A0.1 $0.06 2/15/202338,300 shares $2,106.50 +137.9%N/A0.1 $0.06 1/31/202316,100 shares $821.10 -68.2%N/A0.1 $0.05 1/15/202350,700 shares $2,940.60 +53.6%N/A0.2 $0.06 12/30/202233,000 shares $1,485.00 +11.9%N/A0.1 $0.05 12/15/202229,500 shares $1,416.00 +2,358.3%N/A0.1 $0.05 11/30/20221,200 shares $70.32 -86.8%N/A0 $0.06 11/15/20229,100 shares $682.50 -65.5%N/A0.1 $0.08 10/31/202226,400 shares $1,188.00 -58.8%N/A0 $0.05 10/15/202264,000 shares $3,744.00 -49.7%N/A0.2 $0.06 9/30/2022127,200 shares $8,522.40 +4,286.2%N/A0.3 $0.07 9/15/20222,900 shares $205.90 -62.8%N/A0 $0.07 8/31/20227,800 shares $630.24 -77.5%N/A0 $0.08Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch his stock warning right here, 100% free of charge OTLC Short Interest - Frequently Asked Questions What is Oncotelic Therapeutics' current short interest? Short interest is the volume of Oncotelic Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 1,800 shares of OTLC short. Learn More on Oncotelic Therapeutics' current short interest. Is Oncotelic Therapeutics' short interest increasing or decreasing? Oncotelic Therapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,800 shares, a decrease of 84.2% from the previous total of 11,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oncotelic Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Oncotelic Therapeutics: Edesa Biotech, Inc. (0.69%), FSD Pharma Inc. (1.00%), Ceapro Inc. (0.00%), Cocrystal Pharma, Inc. (0.11%), Pieris Pharmaceuticals, Inc. (1.12%), Avalo Therapeutics, Inc. (10.13%), RedHill Biopharma Ltd. (2.38%), Tonix Pharmaceuticals Holding Corp. (1.89%), Vaxxinity, Inc. (3.61%), Monopar Therapeutics Inc. (1.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Oncotelic Therapeutics stock? Short selling OTLC is an investing strategy that aims to generate trading profit from Oncotelic Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncotelic Therapeutics? A short squeeze for Oncotelic Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLC, which in turn drives the price of the stock up even further. How often is Oncotelic Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLC, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Edesa Biotech Short Interest FSD Pharma Short Interest Ceapro Short Interest Cocrystal Pharma Short Interest Pieris Pharmaceuticals Short Interest Avalo Therapeutics Short Interest RedHill Biopharma Short Interest Tonix Pharmaceuticals Short Interest Vaxxinity Short Interest Monopar Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:OTLC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts